News | August 02, 2024
GlaxoSmithKline Pharmaceuticals reports Q1 FY25 PAT at Rs. 182 Cr
Strong topline growth driven by solid performance across key brands.
Strong topline growth driven by solid performance across key brands.
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
_256_384.jpg)
€ 6.6 million investment at Nantong site expands production capabilities for cell culture media
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
India boasts the largest livestock population, with 536 million livestock and 851 million poultry
Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
Subscribe To Our Newsletter & Stay Updated
